Brief: Stoke Therapeutics Enrolls First Patient In A Natural History Study Of People Living With Autosomal Dominant Optic Atrophy
25/08/2022 12:33
Aug 25 (Reuters) - Stoke Therapeutics Inc STOK.O :
* STOKE THERAPEUTICS ENROLLS FIRST PATIENT IN A NATURAL
HISTORY
STUDY OF PEOPLE LIVING WITH AUTOSOMAL DOMINANT OPTIC ATROPHY
Source text for Eikon: ID:nBw5g4DHLa
Further company coverage: STOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Stoke Therapeutics
See all newsBrief: Stoke Therapeutics Announces Inducement Grants
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics